We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+33.73%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.59B
AUM Growth
+$475M
Cap. Flow
-$61.5M
Cap. Flow %
-2.37%
Top 10 Hldgs %
31.64%
Holding
140
New
7
Increased
46
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$23.1M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$16.6M
3
CI icon
Cigna
CI
+$16.4M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$15M
5
TVTX icon
Travere Therapeutics
TVTX
+$9.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$44.7M
2
LOXO
Loxo Oncology, Inc
LOXO
+$33.8M
3
MOH icon
Molina Healthcare
MOH
+$18.2M
4
WCG
Wellcare Health Plans, Inc.
WCG
+$18M
5
BIIB icon
Biogen
BIIB
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Miscellaneous 1.82%
3 Consumer Staples 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
51
Puma Biotechnology
PBYI
$475M
$17.8M 0.69%
458,000
+1,538
+0.3% +$47K
SGEN
52
DELISTED
Seagen Inc. Common Stock
SGEN
$17.7M 0.68%
242,000
+39,500
+20% +$2.81M
CELG
53
DELISTED
Celgene Corp
CELG
$17.5M 0.67%
185,150
– –
KYNB
54
Kyntra Bio
KYNB
$31.6M
$16.6M 0.64%
12,240
– –
ALLK
55
DELISTED
Allakos
ALLK
$16.4M 0.63%
404,000
– –
IMMU
56
DELISTED
Immunomedics Inc
IMMU
$15.4M 0.59%
800,000
+20,000
+3% +$322K
XENT
57
DELISTED
Intersect ENT, Inc
XENT
$14.9M 0.58%
465,000
– –
SAGE
58
DELISTED
Sage Therapeutics
SAGE
$14.7M 0.57%
92,500
+43,500
+89% +$6.3M
A icon
59
Agilent Technologies
A
$43.3B
$14.7M 0.57%
182,800
– –
CI icon
60
Cigna
CI
$75B
$14.5M 0.56%
+90,000
New +$16.4M
OBSV
61
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.3M 0.55%
1,120,000
– –
GH icon
62
Guardant Health
GH
$23.7B
$13.8M 0.53%
180,000
-36,000
-17% -$2M
WST icon
63
West Pharmaceutical
WST
$25.5B
$13.8M 0.53%
125,000
-35,000
-22% -$3.64M
FOLD
64
DELISTED
Amicus Therapeutics
FOLD
$13.6M 0.52%
1,000,000
– –
BHVN
65
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$13.4M 0.52%
260,000
– –
MRTX
66
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.2M 0.51%
180,000
+30,000
+20% +$2.04M
GBT
67
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13M 0.5%
245,000
– –
ZGNX
68
DELISTED
Zogenix, Inc.
ZGNX
$12.9M 0.5%
235,000
– –
AXGN icon
69
Axogen
AXGN
$2.68B
$12.7M 0.49%
603,970
– –
TBPH icon
70
Theravance Biopharma
TBPH
$885M
$12.5M 0.48%
550,000
– –
ANAB icon
71
AnaptysBio
ANAB
$1.6B
$12.4M 0.48%
170,000
+34,000
+25% +$2.35M
ZLAB icon
72
Zai Lab
ZLAB
$2.83B
$12.2M 0.47%
413,400
+63,400
+18% +$1.74M
BMRN icon
73
BioMarin Pharmaceuticals
BMRN
$12.6B
$12M 0.46%
135,000
+6,000
+5% +$556K
SRGA
74
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$11.7M 0.45%
65,000
– –
PHAS
75
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$10.8M 0.42%
1,140,000
+305,000
+37% +$1.21M
1 2
3
4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rock Springs Capital Management held 140 positions worth $2.59B, up 22% from $2.12B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rock Springs Capital Management's Q1 2019 filing shows 7 new, 46 increased, 13 reduced and 9 closed positions. Its largest new stake was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M. The largest sale was TESARO, Inc., an estimated $44.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Rock Springs Capital Management's largest Q1 2019 buy was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M.
  • Rock Springs Capital Management added most to Portola Pharmaceuticals, Inc. in Q1 2019, an estimated $16.6M increase.
  • Rock Springs Capital Management's biggest Q1 2019 reduction was Molina Healthcare, cutting an estimated $18.2M.
  • Rock Springs Capital Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $44.7M.
  • Rock Springs Capital Management's ten largest holdings make up 32% of its $2.59B portfolio in Q1 2019.
  • Rock Springs Capital Management opened 7 new positions and closed 9 in Q1 2019.
  • Rock Springs Capital Management's portfolio value rose 22% quarter-over-quarter to $2.59B.

Based on Rock Springs Capital Management's 13F filing for Q1 2019, filed 15 May 2019.